Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics

被引:9
作者
Janin, Maxime [1 ,2 ]
Davalos, Veronica [1 ]
Esteller, Manel [1 ,2 ,3 ,4 ]
机构
[1] Josep Carreras Leukaemia Res Inst IJC, Canc Epigenet Grp, Germans Trias & Pujol, Ctra Can Ruti,Cami Les Escoles S-N, Badalona 08916, Spain
[2] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
[3] Inst Catalana Recerca I Estudis Avancats ICREA, Barcelona, Catalonia, Spain
[4] Univ Barcelona UB, Sch Med & Hlth Sci, Physiol Sci Dept, Barcelona, Catalonia, Spain
关键词
Epigenetic; Epitranscriptomic; Cancer metastasis; Cancer treatment; EPITHELIAL-MESENCHYMAL TRANSITION; ISLAND METHYLATOR PHENOTYPE; FRIZZLED-RELATED PROTEIN-1; PROMOTES LIVER METASTASIS; TRANSFER-RNA MODIFICATION; SQUAMOUS-CELL CARCINOMA; CIRCULATING TUMOR-CELLS; REGULATES E-CADHERIN; BREAST-CANCER; COLORECTAL-CANCER;
D O I
10.1007/s10555-023-10120-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Most of the cancer-associated mortality and morbidity can be attributed to metastasis. The role of epigenetic and epitranscriptomic alterations in cancer origin and progression has been extensively demonstrated during the last years. Both regulations share similar mechanisms driven by DNA or RNA modifiers, namely writers, readers, and erasers; enzymes responsible of respectively introducing, recognizing, or removing the epigenetic or epitranscriptomic modifications. Epigenetic regulation is achieved by DNA methylation, histone modifications, non-coding RNAs, chromatin accessibility, and enhancer reprogramming. In parallel, regulation at RNA level, named epitranscriptomic, is driven by a wide diversity of chemical modifications in mostly all RNA molecules. These two-layer regulatory mechanisms are finely controlled in normal tissue, and dysregulations are associated with every hallmark of human cancer. In this review, we provide an overview of the current state of knowledge regarding epigenetic and epitranscriptomic alterations governing tumor metastasis, and compare pathways regulated at DNA or RNA levels to shed light on a possible epi-crosstalk in cancer metastasis. A deeper understanding on these mechanisms could have important clinical implications for the prevention of advanced malignancies and the management of the disseminated diseases. Additionally, as these epi-alterations can potentially be reversed by small molecules or inhibitors against epi-modifiers, novel therapeutic alternatives could be envisioned.
引用
收藏
页码:1071 / 1112
页数:42
相关论文
共 402 条
  • [11] DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation
    Batra, Rajbir Nath
    Lifshitz, Aviezer
    Vidakovic, Ana Tufegdzic
    Chin, Suet-Feung
    Sati-Batra, Ankita
    Sammut, Stephen-John
    Provenzano, Elena
    Ali, H. Raza
    Dariush, Ali
    Bruna, Alejandra
    Murphy, Leigh
    Purushotham, Arnie
    Ellis, Ian
    Green, Andrew
    Garrett-Bakelman, Francine E.
    Mason, Chris
    Melnick, Ari
    Aparicio, Samuel A. J. R.
    Rueda, Oscar M.
    Tanay, Amos
    Caldas, Carlos
    [J]. NATURE COMMUNICATIONS, 2021, 12 (01)
  • [12] DNA methylation and gene silencing in cancer
    Baylin S.B.
    [J]. Nature Clinical Practice Oncology, 2005, 2 (Suppl 1): : S4 - S11
  • [13] RNA Editing in Pathogenesis of Cancer
    Baysal, Bora E.
    Sharma, Shraddha
    Hashemikhabir, Seyedsasan
    Janga, Sarath Chandra
    [J]. CANCER RESEARCH, 2017, 77 (14) : 3733 - 3739
  • [14] Epigenetic plasticity: A central regulator of epithelial-to-mesenchymal transition in cancer
    Bedi, Upasana
    Mishra, Vivek Kumar
    Wasilewski, David
    Scheel, Christina
    Johnsen, Steven A.
    [J]. ONCOTARGET, 2014, 5 (08) : 2016 - 2029
  • [15] Multigene methylation analysis of enriched circulating tumor cells associates with poor progression-free survival in metastatic breast cancer patients
    Benezeder, Theresa
    Tiran, Verena
    Treitler, Alexandra A. N.
    Suppan, Christoph
    Rossmann, Christopher
    Stoeger, Herbert
    Cote, Richard J.
    Datar, Ram H.
    Balic, Marija
    Dandachi, Nadia
    [J]. ONCOTARGET, 2017, 8 (54) : 92483 - 92496
  • [16] HDAC inhibitor suppresses proliferation and invasion of breast cancer cells through regulation of miR-200c targeting CRKL
    Bian, Xuehai
    Liang, Zhongxing
    Feng, Amber
    Salgado, Eric
    Shim, Hyunsuk
    [J]. BIOCHEMICAL PHARMACOLOGY, 2018, 147 : 30 - 37
  • [17] MODOMICS: a database of RNA modification pathways. 2021 update
    Boccaletto, Pietro
    Stefaniak, Filip
    Ray, Angana
    Cappannini, Andrea
    Mukherjee, Sunandan
    Purta, Elzbieta
    Kurkowska, Malgorzata
    Shirvanizadeh, Niloofar
    Destefanis, Eliana
    Groza, Paula
    Avsar, Gulben
    Romitelli, Antonia
    Pir, Pinar
    Dassi, Erik
    Conticello, Silvestro G.
    Aguilo, Francesca
    Bujnicki, Janusz M.
    [J]. NUCLEIC ACIDS RESEARCH, 2022, 50 (D1) : D231 - D235
  • [18] Eukaryotic 5-methylcytosine (m5C) RNA Methyltransferases: Mechanisms, Cellular Functions, and Links to Disease
    Bohnsack, Katherine E.
    Hoebartner, Claudia
    Bohnsack, Markus T.
    [J]. GENES, 2019, 10 (02):
  • [19] SCN4B acts as a metastasis-suppressor gene preventing hyperactivation of cell migration in breast cancer
    Bon, Emeline
    Driffort, Virginie
    Gradek, Frederic
    Martinez-Caceres, Carlos
    Anchelin, Monique
    Pelegrin, Pablo
    Cayuela, Maria-Luisa
    Marionneau-Lambot, Severine
    Oullier, Thibauld
    Guibon, Roseline
    Fromont, Gaelle
    Gutierrez-Pajares, Jorge L.
    Domingo, Isabelle
    Piver, Eric
    Moreau, Alain
    Burlaud-Gaillard, Julien
    Frank, Philippe G.
    Chevalier, Stephan
    Besson, Pierre
    Roger, Sebastien
    [J]. Nature Communications, 2016, 7
  • [20] Interplay between m6A epitranscriptome and epigenome in cancer: current knowledge and therapeutic perspectives
    Bove, Guglielmo
    Amin, Sajid
    Babaei, Mehrad
    Benedetti, Rosaria
    Nebbioso, Angela
    Altucci, Lucia
    Del Gaudio, Nunzio
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (03) : 464 - 475